ERBB2 and gastric cancer: The ToGa (Trastuzumab for Gastric Cancer) trial demonstrated improved overall survival in patients with Her2/neu amplified tumors who received trastuzumab in addition to standard chemotherapy in comparison to chemotherapy alone [6].